01
Dec

As a startup, Editas Medicine quickly enjoyed the spotlight as a pioneer in the field of gene editing. Its founding VCs attracted a high-profile biotech CEO–Katrine Bosley–last summer, and now it also has the IP it needs from a group of leading research institutions in the forefront of developing CRISPR-Cas9 and TALENs technology.

…read more

Source: Top research institutions hand hot gene-editing tech–with a catch–to Editas

    

0 No comments